Navigation Links
Added benefit of dapagliflozin is not proven
Date:6/6/2013

Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy. No such added benefit can be derived from the dossier, however, because the drug manufacturer did not present any relevant data for any of the possible therapeutic indications of dapagliflozin.

Monotherapy or combination therapy possible

Dapagliflozin is approved both as monotherapy and in combination with other blood-glucose lowering drugs, including insulin. As monotherapy it is an option for patients who do not tolerate metformin. Dapagliflozin can also be used as combination therapy, either together with metformin or with sulfonylureas if either of these two drugs alone is insufficient to control blood sugar. Dapagliflozin can also be combined with insulin if the target blood sugar levels cannot be achieved with insulin alone. Other combinations with oral antidiabetics are possible, but these were not presented by the manufacturer in its dossier.

G-BA specified appropriate comparator therapy

The Federal Joint Committee (G-BA) specified a sulfonylurea (glibenclamide or glimepiride) as appropriate comparator therapy for the dapagliflozin monotherapy. The combination therapy of dapagliflozin and metformin was also to be compared with one of these two drugs (each supplemented with metformin). The combination of dapagliflozin with a sulfonylurea was to be tested against metformin in combination with one of the sulfonylureas glibenclamide or glimepiride. According to the G-BA's specifications, the combination of dapagliflozin and insulin was to be compared either with human insulin and metformin, or, if metformin was unsuitable, with human insulin alone.

Monotherapy: patients did not receive approval-compliant treatment

The manufacturer did not submit any direct comparative study between dapagliflozin and one of the sulfonylureas. Instead, it conducted an adjusted indirect comparison based on several studies. In principle, such indirect comparisons can be suitable to prove an added benefit. But the patients in the studies used by the manufacturer were not treated according to the approval status of dapagliflozin as monotherapy because the vast majority were not intolerant to metformin.

Combination with metformin: manufacturer compared with glipizide

Regarding the combination therapy with metformin, the pharmaceutical company did not submit any study that compared dapagliflozin with glibenclamide or glimepiride as the G-BA had specified. Instead, it cited a study that compared dapagliflozin plus metformin with glipizide plus metformin. However, this sulfonylurea has no longer been approved in Germany since 2007. In addition, the manufacturer did not provide sufficient proof in its dossier that glipizide is equivalent to the other two sulfonylureas.

Combination with sulfonylureas: studies were unsuitable

As to the combination therapy with sulfonylureas, the company did not draw on a direct comparative study, but on an adjusted indirect comparison. However, the studies it used were unsuitable: in one case, the glibenclamide dose exceeded the maximum dose approved in Germany, in another case, the drug glipizide, which is not approved in Germany, was used.

Combination with insulin: therapy could not be optimized for the individual patient

Regarding the indication dapagliflozin combined with insulin, the manufacturer used three studies. However, the results of these studies cannot be used for the assessment of the added benefit. The main reason for this is that the insulin therapy could not be tailored sufficiently to the individual patient: even though their current insulin therapy was insufficient, patients were neither supposed to change the insulin nor to adapt the dose. But to be able to draw conclusions about the added benefit, the combination with dapagliflozin would have to be compared with other strategies for optimizing treatment, for example optimizing insulin use.

Not tailoring treatment to the individual patient does not meet the current standard of diabetological practice anyway. In fact, insulin therapy is optimized for the individual patient so that hyperglycaemia and hypoglycaemia do not occur in the first place. So in the studies insulin was not used in a way that would be necessary and appropriate in this indication.

Hence the dossier did not contain study results for any of the four therapeutic indications that would be suitable to prove an added benefit.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.


'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. The Newest Features Added to Dokmee
2. Aflibercept in AMD: No proof of added benefit
3. Hiring of New Sales Engineer Creates Added Value for Customers at Strouse
4. Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity
5. DrugRisks Update: Warning Added to Pradaxa For Blood Condition
6. Younger Men Biggest Consumers of Added Sugars: CDC
7. Finishing Touches Added as Hotel Shangrila Continues to Restore this Streamline Moderne Gem
8. Added benefit of saxagliptin/metformin combination is not proven
9. Left Coast Marijuana Delivery Service Added To Top-Tier Dispensary Locator
10. BPA Added To California’s Toxic Chemicals List Making BPA-Free Dental Products from PureLife More Attractive
11. Astro-Clairvoyant Norah Guide With Premium Astrology Extends Blog Series With Newly Added Video Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment and retention ... and scientific initiatives have all marked the last 12 months at Roswell Park ... of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... After ... Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to ... Scarborough Hospital. He successfully completed his first three-year term as chief and began a ...
(Date:2/5/2016)... ... 05, 2016 , ... US Sports Camps , official operators of Nike ... high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New ... ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... --> --> GAAP ... $130.3 million, up $5.1 million or 4.1% from the ... 7.2% from the fourth quarter of 2014. Revenue for ...
(Date:2/4/2016)... SILVER SPRING, Md. , Feb. 4, 2016 ... Robert Califf , the FDA,s Deputy Commissioner for Medical Products ... far-reaching action plan to reassess the agency,s approach to opioid ... the epidemic, while still providing patients in pain access to ... The FDA will: , Re-examine the risk-benefit ...
(Date:2/4/2016)... India , February 4, 2016 ... the new Market Research Report "North American Automated External ... Fully-Automated External Defibrillators), by End-User (Public Facilities, Hospitals, Homecare ... American automated external defibrillators (AED) report defines and segments ... the revenue. This market is estimated to grow to ...
Breaking Medicine Technology: